[go: up one dir, main page]

DE69434295D1 - Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis - Google Patents

Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis

Info

Publication number
DE69434295D1
DE69434295D1 DE69434295T DE69434295T DE69434295D1 DE 69434295 D1 DE69434295 D1 DE 69434295D1 DE 69434295 T DE69434295 T DE 69434295T DE 69434295 T DE69434295 T DE 69434295T DE 69434295 D1 DE69434295 D1 DE 69434295D1
Authority
DE
Germany
Prior art keywords
hepatitis
virus
cells
human
immunodominant epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69434295T
Other languages
English (en)
Other versions
DE69434295T2 (de
Inventor
Geert Leroux-Roels
Robert Deleys
Geert Maertens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8214764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69434295(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Application granted granted Critical
Publication of DE69434295D1 publication Critical patent/DE69434295D1/de
Publication of DE69434295T2 publication Critical patent/DE69434295T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69434295T 1993-11-04 1994-10-28 Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis Revoked DE69434295T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93402718 1993-11-04
EP93402718 1993-11-04

Publications (2)

Publication Number Publication Date
DE69434295D1 true DE69434295D1 (de) 2005-04-14
DE69434295T2 DE69434295T2 (de) 2006-02-16

Family

ID=8214764

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69433971T Expired - Fee Related DE69433971T2 (de) 1993-11-04 1994-10-28 Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
DE69432475T Revoked DE69432475T2 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
DE69434295T Revoked DE69434295T2 (de) 1993-11-04 1994-10-28 Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69433971T Expired - Fee Related DE69433971T2 (de) 1993-11-04 1994-10-28 Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
DE69432475T Revoked DE69432475T2 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis

Country Status (11)

Country Link
US (4) US6555114B1 (de)
EP (4) EP0992581B2 (de)
JP (2) JPH09504534A (de)
AT (3) ATE290592T1 (de)
AU (1) AU698878B2 (de)
CA (1) CA2175692A1 (de)
DE (3) DE69433971T2 (de)
DK (2) DK0992580T3 (de)
ES (2) ES2239819T3 (de)
PT (2) PT725824E (de)
WO (1) WO1995012677A2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE249838T1 (de) 1993-05-12 2003-10-15 Chiron Corp Konserviertes motiv der hepatitis c virus e2/ns1 region
US7070790B1 (en) * 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
ES2239819T3 (es) * 1993-11-04 2005-10-01 Innogenetics N.V. Epitopos inmunodominantes de celulas t humanas del virus de la hepatitis c.
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
CA2187299A1 (en) * 1994-04-08 1995-10-19 Jay A. Berzofsky Hepatitis c virus core peptide for stimulation of cytotoxic t lymphocytes and diagnosis of hcv exposure
CA2305847A1 (en) 1997-11-06 1999-05-20 Innogenetics N.V. Multi-mer peptides derived from hepatitis c virus envelope proteins for diagnostic use and vaccination purposes
DE69939132D1 (de) 1998-04-17 2008-08-28 Innogenetics Nv Verfahren zur Verbesserung der Proteinkonformation mit Hilfe von Reduktionsmitteln
AU3714499A (en) * 1998-05-14 1999-11-29 Pasteur Merieux Serums Et Vaccins Hepatitis c virus mimotopes
AU748700B2 (en) * 1998-06-12 2002-06-13 Aventis Pasteur HIV virus mimotopes
RU2247729C2 (ru) * 1998-06-24 2005-03-10 Иннодженетикс Н.В. Олигомерная частица, индуцирующая иммунитет против вируса гепатита с, способ получения олигомерной частицы, композиция, специфическое антитело, набор (варианты), иммунологический анализ и вакцина против вируса гепатита с
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
EP1105496B1 (de) 1998-08-21 2007-03-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Modifizierte hcv peptid-impfstoffe
DE19908423A1 (de) * 1999-02-26 2000-08-31 Deutsches Krebsforsch An der Entwicklung des ZNS beteiligtes Protein (TP)
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
EP1535628B1 (de) * 1999-11-24 2013-07-31 Novartis Vaccines and Diagnostics, Inc. Hbv/hcv virus-ähnliche teilchen
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
DE60045776D1 (de) * 2000-09-01 2011-05-05 Epimmune Inc Hla-bindungspeptide und ihre anwendungszwecke
GB0026094D0 (en) * 2000-10-25 2000-12-13 Imp College Innovations Ltd Methods
US7402567B2 (en) * 2000-10-27 2008-07-22 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
US8129349B2 (en) * 2000-10-27 2012-03-06 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
WO2002086101A2 (en) 2001-04-24 2002-10-31 Innogenetics N.V. Core-glycosylated hcv envelope proteins
FR2825093B1 (fr) * 2001-05-28 2003-07-18 Bio Merieux Polypeptide reagissant avecles anticorps de patients infectes par vhc et utilisations
FR2825363A1 (fr) * 2001-05-31 2002-12-06 Bio Merieux Polypeptides reagissant avec les anticorps de patients infectes par vhc et utilisations
US7736677B2 (en) * 2001-06-20 2010-06-15 Metaproteomics, Llc Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
JP2003064096A (ja) * 2001-08-29 2003-03-05 Mitsubishi Kagaku Bio-Clinical Laboratories Inc Ｃ型肝炎ウイルス特異的細胞障害性ｔ細胞認識エピトープ
GB0126782D0 (en) * 2001-11-07 2002-01-02 Medical Res Council Assay
IL162236A0 (en) * 2001-12-18 2005-11-20 Innogenetics Nv Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
US20040126395A1 (en) * 2001-12-18 2004-07-01 Geert Maertens Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US7201904B2 (en) 2002-05-16 2007-04-10 The General Hospital Corporation Epitopes of hepatitis C virus
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
CA2491508A1 (en) * 2002-07-02 2004-01-15 Chiron Corporation Hcv fusion proteins with modified ns3 domains
AU2003283365A1 (en) * 2002-11-08 2004-06-07 Innogenetics N.V. HCV vaccine compositions comprising E1 and NS3 peptides
WO2004069864A1 (fr) * 2003-01-07 2004-08-19 Biomerieux Polypeptides f’ du virus de l’hepatite c, epitopes et leurs applications diagnostiques et therapeutiques
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
KR100790646B1 (ko) * 2004-07-03 2008-01-02 재단법인 목암생명공학연구소 세포매개 면역반응을 효과적으로 유도하는 ｈｃｖ수퍼타입 에피토프, 그를 코딩하는 올리고뉴클레오타이드및 그의 용도
CU23470A1 (es) * 2004-08-11 2009-12-17 Ct Ingenieria Genetica Biotech Vectores vivos recombinantes y su uso en composiciones farmacéuticas contra el virus de la hepatitis c
US7381705B2 (en) * 2004-09-29 2008-06-03 The Administrators Of The Tulane Educational Fund Inhibitors of hepatitis C virus
MX2007004662A (es) * 2004-10-18 2007-11-23 Globeimmune Inc Terapia basada en levaduras para infeccion cronica por hepatitis c.
CA2618429A1 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US20090238822A1 (en) * 2005-10-13 2009-09-24 Virexx Medical Corp. Chimeric Hepatitis C Virus Antigens For Eliciting an Immune Response
US20080031893A1 (en) * 2006-06-20 2008-02-07 Metaproteomics, Llc Acacia based protein kinase modulation cancer treatment
EP2402023A1 (de) * 2006-06-28 2012-01-04 Statens Serum Institut Ausweitung des T-Zell-Repertoires zum Einbeziehen subdominanter Epitope durch Impfung mit als Proteinfragmente oder Peptid-Cocktails abgegebenen Antigenen
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
ES2303496B1 (es) * 2008-02-21 2009-07-07 Fundacion Para El Estudio De Las Hepatitis Virales Metodo analitico perfeccionado para la deteccion de hepatitis c oculta, aplicaciones del mismo y su correspondiente kit de diagnostico.
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
CN107375919B (zh) 2009-03-27 2022-07-29 台湾地区“中央研究院” 抗病毒免疫的方法和组合物
US20120046188A1 (en) * 2009-03-30 2012-02-23 bioMerieux, SA Solid Support for HCV Detection
US20130183376A1 (en) 2010-09-08 2013-07-18 Saitama Medical University Hepatitis c virus liposome vaccine
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
US9550811B2 (en) 2010-12-02 2017-01-24 Bionor Immuno As Peptide scaffold design
US9493514B2 (en) 2011-01-06 2016-11-15 Bionor Immuno As Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes
CA2874923C (en) 2012-06-06 2021-08-31 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
CN105073989A (zh) * 2013-02-19 2015-11-18 国立大学法人神户大学 免疫原性多肽表层表达双歧杆菌
BR112015023355A8 (pt) 2013-03-14 2018-01-30 Abbott Lab antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada.
EP2968526A4 (de) 2013-03-14 2016-11-09 Abbott Lab Hcv-antigen-antikörper-kombinationstest sowie verfahren und zusammensetzungen zur verwendung darin
EP2971046A4 (de) * 2013-03-14 2016-11-02 Abbott Lab Monoklonale antikörper gegen hcv-core lipid-bindender domäne
CN105555310B (zh) * 2013-07-08 2019-07-23 南京传奇生物科技有限公司 一种提高蛋白血清半衰期的组合物和方法
AU2017332854B2 (en) 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
CA3093314A1 (en) 2018-03-16 2019-09-19 The Governors Of The University Of Alberta Hepatitis c virus peptide compositions and methods of use thereof
CN109160942B (zh) * 2018-09-26 2021-06-29 广州市第八人民医院 Hcv包膜蛋白高度保守区域的肽段502-518及其用途
JP2022518488A (ja) * 2019-01-25 2022-03-15 センティ バイオサイエンシズ インコーポレイテッド タンパク質機能を制御するための融合構築物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US6027729A (en) 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
US5639594A (en) * 1990-02-16 1997-06-17 United Biomedical, Inc. Linear and branched peptides effective in diagnosing and detecting non-A, non-B hepatitis
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
AU7679491A (en) * 1990-04-04 1991-10-30 Protos, Inc. Hepatitis c virus protease inhibitors
US5747339A (en) * 1990-06-25 1998-05-05 Research Foundation For Microbial Diseases Of Osaka Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide
KR0181517B1 (ko) * 1990-07-09 1999-04-01 나까하라 노부유끼 비-에이 비-비형 간염-특이 항원 및 간염 진단에서 그의 용도
CA2047792C (en) 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
CA2049679C (en) * 1990-08-24 2005-06-21 Sushil G. Devare Hepatitis c assay utilizing recombinant antigens
CA2055149A1 (en) * 1990-11-08 1992-05-09 Hiroaki Okamoto Non-a, non-b hepatitis virus related antigen, antibody, detection systems, polynucleotides and polypeptides
CA2087974A1 (en) 1991-06-13 1992-12-14 David C. Leahy Immunoassay for non-a non-b hepatitis
WO1993000365A2 (en) * 1991-06-24 1993-01-07 Chiron Corporation Hepatitis c virus (hcv) polypeptides
DE4209215A1 (de) * 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh Hcv peptidantigene und verfahren zur bestimmung von hcv
US5428145A (en) 1991-08-09 1995-06-27 Immuno Japan, Inc. Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
JPH06510191A (ja) * 1991-08-21 1994-11-17 アボツト・ラボラトリーズ Ｎｓ１に対する組換え抗原を利用したｃ型肝炎アッセイ
AU679429B2 (en) * 1991-09-13 1997-07-03 Novartis Vaccines And Diagnostics, Inc. Immunoreactive hepatitis C virus polypeptide compositions
AU2679492A (en) * 1991-09-16 1993-04-27 Abbott Laboratories Hepatitis c assay
CA2128896A1 (en) * 1992-02-04 1993-08-05 Douglas J. Jolly Hepatitis therapeutics
ES2133392T5 (es) 1992-03-06 2004-12-16 N.V. Innogenetics S.A. Procedimiento para la determinacion de peptidos que correspondan a epitopos hcv importantes desde el punto de vista inmunologico.
EP0728764A4 (de) * 1993-10-19 1999-01-20 Ajinomoto Kk Peptide das eine immunantwort gegen hiv unduziert und arzneimittel die esenthaelt zur vorbeugung oder behandlung von aids
ES2239819T3 (es) * 1993-11-04 2005-10-01 Innogenetics N.V. Epitopos inmunodominantes de celulas t humanas del virus de la hepatitis c.
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5543657A (en) * 1994-10-07 1996-08-06 International Business Machines Corporation Single layer leadframe design with groundplane capability

Also Published As

Publication number Publication date
JP2004194668A (ja) 2004-07-15
US6613333B1 (en) 2003-09-02
EP0979867A2 (de) 2000-02-16
DE69434295T2 (de) 2006-02-16
DK0992580T3 (da) 2005-07-11
US6689368B1 (en) 2004-02-10
EP0992580A3 (de) 2000-08-09
PT725824E (pt) 2003-08-29
AU7993294A (en) 1995-05-23
EP0725824A1 (de) 1996-08-14
CA2175692A1 (en) 1995-05-11
EP0725824B1 (de) 2003-04-09
PT992580E (pt) 2005-07-29
DE69433971T2 (de) 2005-09-08
AU698878B2 (en) 1998-11-12
ATE274578T1 (de) 2004-09-15
EP0979867A3 (de) 2007-06-13
WO1995012677A3 (en) 1995-07-27
ES2239819T3 (es) 2005-10-01
DE69432475D1 (de) 2003-05-15
ATE236981T1 (de) 2003-04-15
US20040047877A1 (en) 2004-03-11
ES2197170T3 (es) 2004-01-01
ATE290592T1 (de) 2005-03-15
DK0725824T3 (da) 2003-08-11
DE69432475T2 (de) 2004-03-04
EP0992580B1 (de) 2005-03-09
EP0992580A2 (de) 2000-04-12
US6555114B1 (en) 2003-04-29
WO1995012677A2 (en) 1995-05-11
EP0992581A3 (de) 2001-03-07
EP0992581A2 (de) 2000-04-12
EP0992581B1 (de) 2004-08-25
DE69433971D1 (de) 2004-09-30
EP0992581B2 (de) 2011-05-25
JPH09504534A (ja) 1997-05-06

Similar Documents

Publication Publication Date Title
DE69434295D1 (de) Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
ATE280227T1 (de) Epitope von stress proteinen
DK0523395T3 (da) Seroreaktive områder på proteinerne E1 og E2 i HPV 16
ATE229543T1 (de) Polypeptide des hepatitis c-virus (hiv)
ATE241014T2 (de) Hiv-2 varianten
FI941199L (fi) Immunoreaktiiviset hepatiitti-C-viruksen polypeptidikoostumukset
NO892251D0 (no) Fremgangsmaate ved fremstilling av kokkoidosevaksine ved rekombinante teknikker.
ATE170220T1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
DE69534296D1 (de) Sektretierter E1/E2 Hepatitis C Virus-Komplex erhalten aus C-terminal verkürzten Polypeptiden E1 und E2
ATE205220T1 (de) Hepatitis-a-impfstoff
DK204588A (da) Humane rhinoviruspeptider, fremgangsmaade til deres fremstilling samt vacciner med inhold af saadanne peptider
EP0637631A3 (de) Hoch effiziente Expression eines Polypeptids, das eine modifizierte preS1-Region des grossen Hepatitis B-Virus-Antigens enthält.
ITFI920071A1 (it) Antigeni ricombinanti proteici ad aumentata immunogenicita' contenenti il peptide rappresentato dalla sequenza vqgeesndk
IT1270941B (it) Peptidi di hcv e loro usi.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation